Effect of vildagliptin add-on treatment to metformin on plasma asymmetric dimethylarginine in type 2 diabetes mellitus patients

CAKIRCA, Mustafa; KARATOPRAK, Cumali; ZORLU, Mehmet; KISKAC, Muharrem; Kanat, MUSTAFA; CIKRIKCIOGLU, Mehmet; Soysal, Pinar; HURSITOGLU, Mehmet; CAMLI, Ahmet; ERKOC, Reha; ABDUL-GHANI, Muhammad

doi:10.2147/dddt.s52545

Effect of vildagliptin add-on treatment to metformin on plasma asymmetric dimethylarginine in type 2 diabetes mellitus patients

Atıf İçin Kopyala

CAKIRCA M., KARATOPRAK C., ZORLU M., KISKAC M., Kanat M. , CIKRIKCIOGLU M. A. , et al.

DRUG DESIGN DEVELOPMENT AND THERAPY, cilt.8, ss.239-243, 2014 (SCI İndekslerine Giren Dergi)

Cilt numarası: 8
Basım Tarihi: 2014
Doi Numarası: 10.2147/dddt.s52545
Dergi Adı: DRUG DESIGN DEVELOPMENT AND THERAPY
Sayfa Sayısı: ss.239-243

Özet

Aims: A close association has been demonstrated between increased cardiovascular risk and high asymmetric dimethylarginine (ADMA) levels in type 2 diabetes mellitus (DM) patients. We planned to measure serum ADMA levels in type 2 DM patients using vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor.